Reata Pharmaceuticals
Reata Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States, with significant operations across various regions. Founded in 2008, Reata focuses on developing innovative therapies for serious diseases, particularly in the fields of neurology and rare diseases. The company is renowned for its unique product offerings, including its lead drug, which targets critical pathways in cellular metabolism. Reata's commitment to advancing treatment options has positioned it as a leader in the market, achieving notable milestones in clinical development and regulatory approvals. With a strong emphasis on scientific innovation, Reata Pharmaceuticals continues to make strides in improving patient outcomes and addressing unmet medical needs.
DitchCarbon Score
How does Reata Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Reata Pharmaceuticals's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Reata Pharmaceuticals, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Biogen Inc., and as such, it inherits emissions data and climate commitments from its parent organisation. Reata Pharmaceuticals has not publicly disclosed any specific reduction targets or initiatives. However, it is important to note that its climate commitments and performance metrics are influenced by Biogen Inc.'s sustainability strategies. Biogen has established various initiatives, including participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which aim to reduce greenhouse gas emissions across its operations. As a subsidiary, Reata Pharmaceuticals aligns with Biogen's broader climate goals, although specific targets or achievements for Reata itself have not been detailed. The company is expected to contribute to the overarching sustainability efforts of its parent organisation, focusing on reducing emissions and enhancing environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 60,179,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 187,000 | 000,000 | 00,000 | 00,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 262,358,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Reata Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
